Biotech Values

[DewDiligence]

NEXI IPOs 7.44M* shares @$17.00:

https://www.globenewswire.com/news-release/2021/02/12/2174649/0/en/NexImmune-Announces-Pricing-of-Upsized-Initial-Public-Offering.html

https://www.sec.gov/Archives/edgar/data/1538210/000119312521011521/d216127ds1.htm

[NexImmune is] a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, we have two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

The backbone of our approach is our proprietary Artificial Immune Modulation, or AIM, nanoparticle technology platform. The AIM technology enables us to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. Like natural dendritic cells, the AIM nanoparticles employ natural signaling proteins to deliver specific instructions to specific T cells directing a desired immune response. Importantly, unlike other cell therapy approaches, this is accomplished without any genetic manipulation of the T cell, thereby creating T cell products designed to maintain natural target identification, engagement and killing mechanisms.

It’s not a coincidence that NexImmune is located in Gaithersburg, MD—the senior executives spent time at MedImmune (before and after the AZN buyout).

*Assuming exercise of underwriter’s option.